

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>OIE FEB 28 2006 (use as many sheets as necessary)</p> <p>PTO-1449A (2-03)</p>		COMPLETE IF KNOWN	
		Application Number	10/558,931
		Filing Date	November 30, 2005
		First Named Inventor	Scott D. Edmondson, et al.
		Group Art Unit	
		Examiner Name	
Sheet	1	of	5
		Attorney Docket Number	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
/GS/	8	PCT	WO 03/082817 A2	MERCK & CO., INC.	10/09/2003
	9	PCT	WO 03/000180 A2	MERCK & CO., INC.	01/03/2003
	10	PCT	WO 03/000181 A2	MERCK & CO., INC.	01/03/2003
	11	PCT	WO 03/000181 A3	MERCK & CO., INC.	01/03/2003
	12	PCT	WO 02/076450 A1	MERCK & CO., INC.	10/03/2002
	13	PCT	WO 2004/007468 A1	MERCK & CO., INC.	01/22/2004
	14	PCT	WO 2004/032836 A2	MERCK & CO., INC.	04/22/2004
	15	PCT	WO 2004/050022 A2	MERCK & CO., INC.	06/17/2004
▼	16	PCT	WO 2004/058266 A1	MERCK & CO., INC.	07/15/2004
	17	PCT	WO 2004/064778 A2	MERCK & CO., INC.	08/05/2004

Examiner Signature	/Golam Shameem/	Date Considered	08/25/2007
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN		
				Application Number	10/558,931	
				Filing Date	November 30, 2006	
				First Named Inventor	Scott D. Edmondson, et al.	
				Group Art Unit		
				Examiner Name		
Sheet	2	of	5	Attorney Docket Number		21431P

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)	
/GS/	18	PCT	WO 2004/069162 A2	MERCK & CO., INC.	08/19/2004
	19	PCT	WO 02/02560 A2	NOVO NORDISK A/S	01/10/2002
	20	PCT	WO 01/96295 A2	NOVARTIS AG	12/20/2001
	21	PCT	WO 01/96295 A3	NOVARTIS AG	12/20/2001
	22	PCT	WO 01/34594 A1	Guilford Pharmaceuticals, Inc.	05/17/2001
	23	PCT	WO 00/34241	NOVARTIS AG	06/15/2000
	24	PCT	WO 98/19998 A2	NOVARTIS AG	05/14/1998
	25	PCT	WO 98/19998 A3	NOVARTIS AG	05/14/1998
	26	PCT	WO 97/40832	Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
✓	27	PCT	WO 03/000180 A3	MERCK & CO., INC.	01/03/2003

Signature /Golam Shameem/ Considered 08/25/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>		COMPLETE IF KNOWN	
		Application Number	10/558,931
		Filing Date	November 30, 2005
		First Named Inventor	Scott D. Edmondson, et al.
		Group Art Unit	
Examiner Name			
Sheet	3	of	5
		Attorney Docket Number	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
/GS/	28	PCT	WO 02/02560	A3	NOVO NORDISK	01/10/2002
	29	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001
	30	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004
	31	PCT	WO 2004/007468		MERCK & CO., INC.	01/22/2004
	32	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004
	33	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004
	34	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004
	35	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005
↓	36	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005
	37	PCT	WO 2005/002530	A2	SMITHKLINE BEECHAM CORP.	01/09/2003

Examiner Signature /Golam Shameem/ **Date Considered** 08/25/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Drawing through citation if not in conformance and not worthy of citation.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/558,931
				Filing Date	November 30, 2005
				First Named Inventor	Scott D. Edmondson, et al.
				Group Art Unit	
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	21431P

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of reference cited.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/558,931
				Filing Date	November 30, 2006
				First Named Inventor	Scott D. Edmondson, et al.
				Group Art Unit	
Examiner Name					
Sheet	5	of	5	Attorney Docket Number	21431P

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
/GS/	43	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166(2004).			
	44	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102(2004).			
	45	K. Augustyns et al., " Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510(2003).			
	46	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942 (2000).			
	47	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol.12, pp. 87-100 (2004).			
	48	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, pp. 177-188 (2004).			
	49	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem, Vol. 47, pp. 4128-4134 (2004).			
	50	A. E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem, Vol. 47, pp. 4135-4141 (2004).			
	51	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, pp. 589-596 (2004).			
	52	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, pp. 2181-2189 (2004).			
	53	K. Augustyns, et al., "Inhibitors of proline-specific dipeptidyl peptidase: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes", Expert Opin. Ther. Patents, Vol. 15(10), pp. 1387-1407 (2005).			
↓	54	Hans-Ulrich Demuth, et al., " Type 2 diabetes - Therapy with dipetidyl peptidase IV inhibitors", Biochimica et Biophysica Acta, Vol. 1751, pp., 33-44 (2005).			

Examiner Signature	/Golam Shameem/	Date Considered	08/25/2007
--------------------	-----------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005